JEMIQTA
LIVE

Serial Number

99281818

Owner

H. Lundbeck A/S

Attorney

Maren Perry

Filing Date

Jul 14, 2025

Add to watchlist:

No watchlists yet
View on USPTO

JEMIQTA Trademark

Serial Number: 99281818 • Registration: 8137171

JEMIQTA is a trademark filed by H. Lundbeck A/S on July 14, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

H. Lundbeck A/S (398 trademarks)

Ottiliavej 9
DK-2500 Copenhagen-Valby , DK

Entity Type: 03

Trademark Details

Filing Date

July 14, 2025

Registration Date

February 10, 2026

Published for Opposition

December 23, 2025

Goods & Services

Medical apparatus, namely, infusion and injection devices for administering drugs; Medical syringes, intravenous bags sold empty for intravenous therapy, intravenous (IV) feeding tubes, intravenous (IV) infusion pumps, and intravenous (IV) catheters; injection devices for administering drugs, syringes and needles for injections and medical purposes; Apparatus and instruments for diagnostic purposes, namely, dosage management dispensers for administering medicines, incorporating downloadable and recorded software for medical information management for use in web-based physical and psychological examination and assessment of patients at a distance and at a clinic; Medical devices and instruments for use in the diagnosis, medicine administration, monitoring, assessment, control and examination of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases; integrated medical systems comprising of medical instruments for diagnostics and examination of patients and downloadable software for processing patient intake and communications and information management, all for use in the examination and assessment of patients and clients; integrated medical systems comprised of medical instruments for treating central nervous system diseases and disorders and psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases, all for the purposes of management, measurement, monitoring, evaluation, control, collection, storage, transmission and examination of patient and client data and information; medical instruments, namely, devices for delivery and administering of medicines in the nature of infusion and injection devices and infusion pumps for providing medication administering information, guidance, and management

Sanitary preparations for medical purposes; dietetic preparations for medical use; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases of, generated from and affecting the central nervous system; pharmaceutical preparations and substances for the treatment of central nervous system disorders; central nervous system stimulants; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances for diagnosis, prevention and treatment of dementia, Alzheimer's disease, depression, psychosis, anxiety, Lennox-Gastaut disease, epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathy (DEE), alpha-synucleinopathies, Multiple System Atrophy (MSA), dementia with Lewy bodies, rapid eye movement (REM) sleep behavior syndrome, porphyria, Huntington's disease, insomnia, Parkinson's disease, sclerosis, multiple sclerosis, schizophrenia, bipolar disorder, cancer, pain, migraine, headache, Horton's headache, traumatic brain injury, post-traumatic brain injury, dizziness, seizures, stroke, cognitive impairment, cognitive disorders and diseases, mood disorders, falls, movement disorders and diseases, tremor, agitation, mania, aggression, autism, melancholia, Obsessive Compulsive Disorder (OCD), Tourette's syndrome, restlessness, akathisia, fatigue, somnolence, nausea, Cushing's disease, Adrenogenital syndrome (AGS), narcolepsy, Post-Traumatic Stress Disorder (PTSD), Attention Deficit Hyperactivity Disorder (ADHD), Progressive Supranuclear Palsy (PSP), Thyroid Associated Orbitopathy (TAO), Graves Orbitopathy, Hashimoto's Thyroiditis, alcoholism and addiction; diagnostic agents and preparations for medical purposes; chemical substances for diagnostic and medical purposes, namely, chemical reagents for medical use, diagnostic chemical reagents for medical purposes; medical diagnostic reagents

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 10, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 10, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 23, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 23, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 17, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 25, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 24, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 23, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 23, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 23, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 19, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 14, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jul 14, 2025 MAFR
NEW APPLICATION ENTERED
Jul 14, 2025 NWAP